For research use only. Not for therapeutic Use.
Clivatuzumab（Cat No.:I041519）is a monoclonal antibody that targets the tumor-associated antigen CD166 (also known as ALCAM), which is expressed on various cancer cells, including those in pancreatic cancer. By binding to CD166, Clivatuzumab aims to inhibit tumor growth and potentially enhance the immune system’s ability to attack cancer cells. It has been investigated primarily in the treatment of pancreatic cancer, often in combination with other therapies. Clinical trials have assessed its safety, efficacy, and potential to improve patient outcomes, though more research is needed to determine its long-term effectiveness.
| Catalog Number | I041519 |
| CAS Number | 1622075-09-5 |
| Purity | ≥95% |
